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Abstract
The Bcl-2 family encompasses a diverse set of apoptotic regulators that are dynamically activated
in response various cell intrinsic and extrinsic stimuli. An extensive variety of cell culture
experiments have identified effects of growth factors, cytokines and drugs on BCL-2 family
functions, but in vivo studies have tended to focus on role of one or two particular members in
development and organ homeostasis. Thus, the ability of physiologically relevant contexts to
modulate canonical dependencies that are likely to be more complex has yet to be investigated
systematically. In this study, we report findings derived from a pool-based shRNA assay that
systematically and comprehensively interrogated the functional dependence of leukemia and
lymphoma cells upon various BCL-2 family members across many diverse in vitro and in vivo
settings. This approach permitted us to report the first in vivo loss of function screen for modifiers
of the response to a frontline chemotherapeutic agent. Notably, our results reveal an unexpected
role for the extrinsic death pathway as a tissue-specific modifier of therapeutic response. In
particular, our findings demonstrate that particular tissue sites of tumor dissemination play critical
roles in demarcating the nature and extent of cancer cell vulnerabilities and mechanisms of
chemoresistance.
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Introduction
Chemotherapy represents a major treatment modality for cancer, and numerous genetic
screens have probed the mechanisms underlying cell-intrinsic resistance or sensitivity to
front-line chemotherapy (1–6). However, these studies, while informative, have not been
adapted to relevant tumor microenvironments, which may contain diverse stromal and/or
immune cell types, are subject to immune surveillance, and harbor physical barriers to drug
delivery (7). Additionally, the native tumor microenvironment comprises a diverse mixture
of chemokines and cytokines that may impact responses to genotoxic agents (8, 9). Thus, the
central determinants of therapeutic outcome may be highly dependent upon paracrine
survival or stress signals. Indeed, it is well documented that gene function and relevance can
vary dramatically when compared in vivo versus in vitro (8, 10). Consequently, studying the
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impact of defined genetic alterations on therapeutic response in native tumor
microenvironments is critical for effective drug development, personalized cancer regimens,
and the rational design of combination therapies.
Recent advances in the development of tractable mouse models of cancer have, for the first
time, enabled the examination of complex sets of defined alterations in individual mice. For
example, retroviral infection of murine hematopoietic stem cells or primary embryonic
hepatocytes with small pools of short hairpin RNAs (shRNAs), followed by adoptive
transfer into lethally-irradiated recipient mice, has been used to screen for suppressors of B
cell lymphomagenesis or hepatocellular carcinoma (11, 12). Additionally, ex vivo
manipulation of lymphoma cells followed by transfer into syngeneic recipient mice has
permitted the interrogation of thousands of shRNAs for modulators of tumor growth and
dissemination (13). These screens provide powerful proofs of principle that diverse
alterations can be introduced in chimeric tumor models in vivo and that these systems might
permit the simultaneous examination of the relevance of a whole set of genes to therapeutic
response in relevant physiological contexts.
Front-line cancer therapies generally exert their effects by modulating the proportion of pro-
to anti- apoptotic death regulators, most notably members of the Bcl-2 family (14, 15). Thus,
we reasoned that interrogating Bcl-2 family functionality might provide a high-resolution
focus on a crucial facet of cytotoxic cellular responses to chemotherapy in a variety of
distinct settings. Notably, previous studies using recombinant BH3 peptides in reconstituted
mitochondrial suspensions have systematically identified cellular states associated with the
loss of function of one of the BH3-only Bcl-2 family members, the loss of function of a
multi-domain pro-apoptotic Bcl-2 family member, or the enhanced function of an anti-
apoptotic family member; these states characterize the potential range of dysregulation that
the Bcl-2 family can acquire during tumorigenesis and demarcate central cell fate decisions
that are susceptible to therapeutic intervention (16, 17). However, this approach, while quite
powerful, does not allow for the comprehensive examination of the role and relevance of
individual Bcl-2 family members to cell death following chemotherapy. Here we describe a
complementary in vivo screening approach that provides a detailed assessment of the role of
each Bcl-2 family member in the response to chemotherapy in heterogeneous tumor
environments.
Materials and Methods
shRNA generation
shRNAs targeting the Bcl-2 family (18) were designed using Biopredsi from Novartis.
shRNAs were cloned into the MLS (19) retroviral vector containing a Mir30 expression
cassette under the transcriptional control of the MSCV LTR and coexpressing GFP.
Plasmids were verified for mRNA target knockdown using standard qRT-PCR techniques.
Western blots were performed to analyze total protein knock down for a subset of Bcl-2
family members. Bim, Bax, and Bak knockdown are shown in Supp. Figures S1A and B.
The shRNA library was constructed by evenly pooling individual minipreps of each
individual shRNA. This mixture was co-transfected into Phoenix retroviral packaging cells
and pooled virus was collected.
Western Blots
SDS-PAGE was performed according to standard protocols, and gels were transferred to
PVDF membranes. The antibodies used were as follows; Bid (polyclonal antisera from
Honglin Li), BAX (Cell Signaling Technologies #2772), BAK (Upstate #06-536 ), BIM
(Cell Signaling Technologies #C34C5 ), Caspase 8 (Cell Signaling Technologies #D35G2),
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beta-Actin (Cell Signaling Technologies #4967L), and Tubulin (ECM Biosciences
#TM1541).
Luminex bead-based assay
Carboxylated Luminex beads were purchased from Mirai biosystems. Probe
oligonucleotides comprised of the shRNA anti-sense strand modified with C12-amine were
conjugated to the beads using EDC in a pH 4.5 MES hydrate buffer. Coupling efficiency
was validated with sense oligonucleotides. 3500 beads were added to a 50μl reaction volume
in a 3M Tetra-methyl ammonium chloride (TMAC) buffer to reduce the differences in Tm
that accompany differences in GC content. DNA loading concentrations are as indicated
(2-200ng per well were added). Blocking oligos that corresponded to the biotinylated PCR
product but lacked the sense portion of the shRNA were added at 100-fold molar excess to
compete out the dsPCR product and reduce the preferential re-hybridization of the PCR
product. Samples were denatured for 3 min at 95°C and hybridized for 30 minutes at 52°C.
Streptavidin-PE (Invitrogen)/TMAC was then added to the wells and incubated for 5
minutes at 52°C. All samples were incubated at 52°C to ensure they stayed at equilibrium,
and the PMT setting on the Luminex machine was approximately 520 volts (low
calibration).
Polymerase Chain Reaction
Three individual 25μl PCR reactions were performed using a 5’ primer targeting the
constant hairpin loop region and a 3’ primer targeting the vector backbone. The PCR buffer
was 2x Failsafe Buffer B (Epicentre Biotechnologies) and we ran 35 cycles with an
extension time of 1 minute at 72°C and a hybridization temperature of 52°C for 35 seconds.
The 3’ primer was biotinylated. Pooled PCR product was column purified and resuspended
in 36μl water prior to serial dilution and subsequent measurement.
Cell culture
All lymphoma and leukemia cells were isolated directly from tumor-bearing animals and
cultured at 5% CO2 at 37°C. Eμ-Myc p19ARF−/− cells were isolated and maintained as
described (5). B-ALL cells were maintained as described (20). All in vitro viral transduction
was performed by co-infecting 1 million cells per 10cm plate. Infection efficiency was
quantified by flow cytometry for GFP+ cell populations. Infection efficiencies under 50%
were utilized to ensure an MOI of approximately one. Pool composition was measured at the
beginning of the experiment, as well as following recovery from an LD90 doxorubicin drug
dose. Untreated cells that had grown in culture for the duration of the experiment were used
as controls. Hairpin 97mer sequences in the Mir30 context were:
shBid-1-
TGCTGTTGACAGTGAGCGCCACAGAAGATTCCATATCAAATAGTGAAGCCA
CAGAT GTATTTGATATGGAATCTTCTGTGATGCCTACTGCCTCGGA,
shBid-2-
TGCTGTTGACAGTGAGCGCCACAGAAGATTCCATATCAAATAGTGAAGCCA
CAGAT GTATTTGATATGGAATCTTCTGTGATGCCTACTGCCTCGGA.
shCaspase 8-
TGCTGTTGACAGTGAGCGAAACTATGACGTGAGCAATAAATAGTGAAGCCA
CAGAT GTATTTATTGCTCACGTCATAGTTCTGCCTACTGCCTCGGA
Background distribution analysis for in vivo screening data
454 sequencing data used to determine CV thresholds is available from the GEO database
(accession number GSE16090). Coefficients of variation were calculated by dividing the
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standard deviation of the fold change in read number (for any hairpin with >4 reads) by the
mean of the fold change. To be included in this analysis hairpins had to be present at high
enough quantities to have at least 4 reads. Previously validated hit CVs (13) included IL-6,
Lyn, Rac2, Twf, and CrkL and were compared to the background distribution by t-test.
Cumulative distributions were plotted in Matlab using the dfittool.
In vivo screening
6-week old C57BL/6J mice (Jackson Laboratories) were tail vein injected with 2 million Eμ-
Myc p19ARF−/− lymphoma cells expressing the 22 shRNAs targeting the Bcl-2 family.
Infection was optimized such that each tumor cell expressed a single shRNA. We sampled
pool composition before injection, upon the development of a palpable tumor burden, and
upon relapse following IP injection of 8mg/kg of doxorubicin. For in vivo screen validation,
pure populations of cells expressing shRNAs were isolated by GFP sorting using a FACS
ARIA cell sorter. 2 million cells transduced with a vector control or specific shRNAs were
injected into syngeneic recipient mice. At the presentation of palpable lymphomas, mice
were treated with 10mg/kg doxorubicin and disease free survival/tumor free progression
were monitored.
Screening analysis
Luminex intensities for serial dilutions of PCR samples from pooled hairpin libraries were
compared by calculating a curve fit for a given sample using the equation
(Y=a*(1−exp(−b*x)). Sample integrals were then calculated, and these integral scores were
compared after subtracting the initial from the final integral score. All independent Luminex
runs were normalized to the maximum signal intensity and all runs performed on different
days contained internal standards for day-to-day normalization. Scoring shRNAs were
identified following a three-step process. First, in order to eliminate a systematic error for
depleting hairpins, we transformed all the data by adding the hairpin mean to all in vivo
measurements. We then applied two filters. The first filter was based upon a comparison of
the distribution of a given shRNA with the variation of neutral hairpins. We required our
“hits” to have a coefficient of variation that was equal to or less than 0.4. This allowed us to
threshold out approximately 80% of neutral hairpins. The second filter was based upon a
comparison of treated samples with untreated hairpin samples. To progress to further
validation efforts, we required our treated sample to be different at the 0.10 significance
level versus untreated controls.
Data analysis
Linear fits were calculated using a least squares algorithm. Sequences were compared for
overlap using the local alignment method of Smith-Waterman in the Matlab function
localalign.m. Heat maps were generated in Matlab. Kaplan Meier analyses were performed
using Graph Pad Prism software.
Results
A bead-based assay for the direct measurement of pooled shRNA representation
The Bcl-2 family consists of 16 pro- and 6 anti-apoptotic proteins that regulate programmed
cell death in response to a diverse set of intrinsic and extrinsic death stimuli (21, 22). To
assess how these genes modulate chemotherapy-induced cell death across multiple in vivo
contexts, as well as across diverse in vitro conditions in a multiplexed manner, we adapted a
validated set of shRNAs targeting all 22 Bcl-2 family members to Luminex bead-based
analysis (Figure 1A and (18)). This technology has previously been used to quantify diverse
sets of microRNAs in solution with improved accuracy relative to classic microarray
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approaches (23). Thus, we reasoned that this approach could be modified to perform
reproducible quantification of sub-genome sized shRNA pools.
Briefly, we covalently coupled an amino modified oligonucleotide that is the reverse
complement of the unique guide strand section of each shRNA to fluorescently labeled
Luminex beads. Our PCR strategy uses a forward primer complementary to the microRNA
loop sequence present in all hairpins and a biotinylated reverse primer complementary to the
flanking microRNA sequence (Figure 1B). Thus, all shRNA guide strands can be amplified
using common primers, and the quantity of individual shRNAs can be visualized with
streptavidin-PE after bead hybridization. Notably, this approach is distinct from barcoded
shRNA libraries, in which shRNAs are identifiable by a flanking DNA sequence. In this
case, we used the unique portion of the shRNA, itself, as the barcode. This allows for
multiplexed shRNA quantification in any vector backbone.
As an initial proof-of-principle experiment, we confirmed that each Bcl-2 shRNA could be
quantified by Luminex bead hybridization when starting with similar concentrations of
dsPCR product (Supp. Figure S2A). Importantly, while each PCR product with a cognate
bead was readily detectable, a control probe exhibited no significant signal with any of the
22 shRNAs in the plasmid library. In fact, the average maximum signal for an shRNA
present in the pool was approximately 100-fold higher than the control probe signal. While
this negative control ruled out any large magnitude non-specific hybridization, we wanted to
rule out smaller amounts of cross hybridization as the source of the variation in the
maximum fluorescence intensity of the various probes (Supp. Figure S2B). To this end, we
noted a strong relationship between probe GC content and maximum signal intensity.
Oligonucleotides deviating from this relationship were analyzed for local sequence
alignments across the entire shRNA library utilizing the dynamic programming method of
Smith-Waterman (24). The variation in the average local alignment bit scores for all
“outlier” probes was highly similar (Supp. Figure S2C), indicating that cross-hybridization
is an unlikely contributor to overall signal intensity. Thus, oligonucleotide sequences chosen
for optimal siRNA performance are well suited for hybridization-based sequence
identification.
We next performed mock enrichment experiments in which known concentrations of
genomic DNA from single hairpin infected Eμ-Myc p19Arf−/− lymphoma cells were
combined at distinct ratios (Supp. Figure S2D). These lymphoma cells were derived from a
well-established pre-clinical mouse model of Burkitt’s lymphoma and represent a tractable
setting to investigate the genetics of therapeutic response (25, 26). Using these cells, we
observed a linear and highly reproducible change in measured fluorescence intensity that
tightly correlated with the known fold enrichment of the control sample across 8 fold
changes in relative DNA abundance.
The BCL-2 family differentially modulates therapeutic response in distinct B-cell tumors
The initial validation of our measurement technology led us to benchmark this approach
against an established single shRNA flow cytometry based assay. In this assay, GFP was
used as a surrogate marker for the presence of each of 16 distinct Bcl-2 family member
shRNAs, and the impact of gene suppression was determined by the relative change in the
percent of GFP positive cells following treatment (18). In each case, we examined the effect
of Bcl-2 family gene knockdown on the in vitro response of Eμ-Myc p19Arf−/− lymphoma
cells to the front-line chemotherapeutic doxorubicin (Figure 1C). A linear relationship
(r2=0.89) was observed between multiplexed bead-based measurements and single shRNA
flow cytometry measurements of shRNA enrichment and depletion following doxorubicin
treatment. Thus, a bead hybridization assay can rapidly and accurately measure shRNA pool
composition following drug selection.
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A key advantage of shRNA pool-based approaches lies in their inherent adaptability to
diverse experimental systems and conditions. In order to test the flexibility of our system,
we examined the effects of Bcl-2 family member suppression on doxorubicin response in a
distinct cell line. In this case, we examined cells derived from a BCR-Abl driven murine
model of B cell acute lymphoblastic leukemia (B-ALL) (27). As observed in the Burkitt’s
lymphoma model, we could identify a robust Bcl-2 family shRNA drug resistance and
sensitivity profile in these cells. However, the shRNA signatures were distinct between cell
types. The most obvious feature differentiating the two cell lines was the critical role for the
BH3-only member Bim in doxorubicin-induced cell death in B-ALL (Figure 1D). Since Bim
levels are known to increase in response to environmental but not genotoxic stress, the
involvement of Bim in the response to a DNA damaging agent in this context was
unexpected. In order to explore the mechanism of Bim induced cell death, we examined Bim
levels in p185+ BCR-Abl ALL cells treated with genotoxic agents (doxorubicin and
chlorambucil) and a histone deacetylase inhibitor known to promote significant Bim
induction (SAHA) in B cell malignancies (28). Notably, protein levels of Bim were induced
acutely following treatment with DNA damaging agents in B-ALL cells (Figure1E). These
data highlight the potential of pool-based shRNA approaches to identify tumor cell-specific
determinants of therapeutic response.
An in vivo screen for microenvironment specific modifiers of therapeutic response
A central challenge in the development of effective anti-cancer approaches is to understand
the impact of the tumor microenvironment on therapeutic response. To test whether our
system could be used to examine cancer therapy in vivo, we performed a screen to identify
Bcl-2 family members that modulate the response of lymphomas to doxorubicin. Here, all
Bcl-2 family shRNAs were simultaneously co-transfected into viral packaging cells to
produce a multi-construct viral pool (Figure 2A). The resulting pool was used to infect
primary Eμ-Myc p19Arf−/− lymphoma cells ex vivo, and transduced cells were tail-vein
injected into syngeneic recipient mice. A cohort of 8 mice was sacrificed following tumor
onset, and a second cohort was treated with 8mg/kg doxorubicin. Following tumor relapse,
lymphoma cells were harvested from lymph nodes and the thymus, two common sites of
lymphoma manifestation in the Eμ-Myc mouse (25), and the relative shRNA content was
compared between untreated and treated tumors in these distinct tumor microenvironments.
A striking feature of the resulting data was the mouse-to-mouse variability in hairpin
composition following drug treatment. This suggests that the complexity of the in vivo
microenvironment can substantially influence the measured effect of a relatively neutral
shRNA. Further inspection of this variation suggested that a subset of shRNAs exhibited a
level of variation comparable to the in vitro data while the remainder showed significantly
higher fluctuation (Figure 2B). If otherwise neutral hairpins exhibit larger variation in in
vivo datasets, the size of this variation may represent a meaningful discriminator to focus on
hairpins whose effects are large and reproducible enough to overcome this variability. To
determine whether such variation is a consistent feature of in vivo data sets, we made use of
a comprehensive in vivo versus in vitro shRNA screening data set (13). Indeed, most
shRNAs exhibited high mouse-to-mouse CVs in vivo (Figure 2C). However, when we
focused on shRNAs shown to exert a biological effect in subsequent validation experiments,
we saw a significant decrease in shRNA CVs (p<0.01). Thus, variation present in this
established data set can be used to generate a CV threshold that identifies shRNAs with a
high probability of exerting a relevant biological effect. This cutoff was then employed to
filter data generated using our Luminex approach (Figure 2D). As a test of the relevance of
this variation cutoff to other drug screens, we examined the stochastic variation in the
representation of vector control infected Eμ-Myc tumor cells following treatment with the
microtubule poison vincristine in vivo. Here, we transplanted tumor cells into recipient mice
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at a defined infection efficiency, as monitored by GFP expression, and examined the
variation in the percentage of GFP positive cells in distinct mice following treatment.
Importantly, these controls exhibited an in vivo CV that was greater than the doxorubicin
variation cutoff (Supp. Figures S3A and B), suggesting that the CV threshold established in
this study may be broadly applicable to other data sets.
As additional criteria for examining in vivo screening data, we required that shRNA target
mRNAs be present in untransduced lymphoma cells and that the representation of a
“scoring” shRNA be significantly enriched or depleted as a consequence of doxorubicin
treatment (see methods). The resulting list of scoring shRNAs included Bcl-2 family
members previously described to influence therapeutic response (17) (Figure 2D and Supp.
Table S1). For instance, we found that suppression of the BH3-only protein Puma promoted
doxorubicin resistance in both the lymph node and thymus compartments, consistent with
previous reports examining either B lymphoma cells or thymocytes (26, 29). Thus, this
approach can readily identify important regulators of drug-induced cell death.
The extrinsic death pathway is a thymus specific mediator of therapeutic response
Interestingly, in contrast with Puma and other general cell death regulators, we identified the
pro-apoptotic Bcl-2 family member Bid as a specific mediator of doxorubicin cytotoxicity in
the thymus but not in the lymph nodes. To validate and extend the genetic result in light of
this finding, we performed an in vivo GFP competition assay in the spleen, bone marrow,
peripheral lymph nodes and thymus. In this assay, GFP positivity is used as a surrogate
marker for the presence of a Bid shRNA, and the impact of Bid suppression is determined
by the relative change in the percent of GFP positive tumor cells. Consistent with the initial
screening data, Bid loss impaired lymphoma cell death in the thymic tumor
microenvironment, but not other tumor microenvironments (Figure 3A and B). This tissue
specificity was not due to the selective expression of these proteins in specific tumor
microenvironments, as we observed similar levels of Bid and its upstream regulator Caspase
8 in the tumor-bearing lymph node and thymus (Supp. Figure S4A and B). Notably, Bid is
unique among Bcl-2 family members in that it translocates to the mitochondria following
extrinsic activation of death receptors (30, 31). Thus, these data are consistent with a
mechanism whereby constitutively present Bid is activated following the release of secreted
factors or tumor-stromal cell interactions that are specific to the treated thymic
microenvironment.
The relevance of Bid to DNA damage-induced death remains a subject of debate (32, 33).
To confirm the importance of Bid to doxorubicin-induced cell death in vivo, we injected
three cohorts of syngeneic mice with Eu-Myc p19Arf−/− lymphoma cells expressing one of
two validated shRNAs targeting Bid or a vector control. At tumor onset, all mice were
treated with 10mg/kg doxorubicin and monitored for tumor regression and relapse.
Suppression of Bid resulted in decreased tumor free survival and tumor cell clearance
compared to control tumors (Figure 4A). Furthermore, in mice bearing shBid-transduced
lymphomas, 50% of the mice showed no tumor free survival while 90% of control mice
exhibited a period of tumor free survival. Notably, in the case of the lymphoma cells used in
this study, suppression of Bid in vitro had minimal effect on lymphoma cell survival
following doxorubicin treatment (Figure 4B). Thus, treatment of these tumors in their native
microenvironment reveals genetic dependencies that are not present in cultured cells.
These data suggest that activation of components of the extrinsic cell death pathway
potentiate chemotherapeutic efficacy in the thymus. To further interrogate the role of death
receptor signaling in therapeutic response in this setting, we targeted Caspase 8, the direct
activator of Bid by generating hairpins targeting Caspase 8 (Supp. Figure S4C). Suppression
of Caspase 8 in transplanted lymphomas phenocopied the effect of Bid silencing as
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measured by tumor free survival (Figure 5A), suggesting an upstream induction of death
receptor signaling in the thymus following doxorubicin treatment.
Finally, to confirm the specificity of Bid-induced cell death in the thymus relative to whole
organism chemotherapeutic response, we examined the effect of Bid suppression on tumor
free survival following doxorubicin treatment in athymic mice. Pure populations of either
shBid or vector control transduced lymphoma cells were transplanted into surgically
thymectomized recipient mice. Upon the presentation of a palpable disease burden, mice
were dosed with 10mg/kg of doxorubicin and monitored for tumor-free and overall survival.
In this context, chemotherapeutic response was indistinguishable in the presence or absence
of Bid (Figure 5B).
Discussion
We have presented a tractable methodology for pooled shRNA screens that can be rapidly
adapted to diverse vector systems and gene families. The value of this system is exemplified
by the rapid manner in which drug function can be interrogated in multiple cell types in vitro
and in diverse anatomical contexts in vivo. Importantly, while numerous cell culture-based
loss of function screens have been performed to identify modulators of therapeutic response,
this is the first report to describe an in vivo loss of function therapy screen – the relevance of
which is apparent in light of the discordant in vitro and in vivo phenotypes resulting from
Bid suppression. While the set of shRNAs probed in this work is restricted to a particular
aspect of cell biology, recent advances in bead-based DNA hybridization now permit the
simultaneous resolution of as many as 500 distinct oligonucleotides so that multiple facets
can be explored simultaneously. We have recently shown that as many as 1000 distinct
shRNAs can be introduced into individual mice (13), suggesting that large shRNA libraries
can be combined with this technology to probe the impact of myriad genetic lesions in
diverse pathophysiological contexts.
In this study we systematically examined shRNAs targeting the entire Bcl-2 family in
multiple in vitro and in vivo settings. In all therapeutic contexts, we identified a specific
BH3 “activator” gene essential for mediating the effects of frontline chemotherapy.
Biochemical studies have previously defined critical roles for the BH3 only family members
Bid, Puma and Bim. Furthermore, the recent development of a Bid, Puma, and Bim triple
knockout mouse confirmed the essential role of these proteins in developmentally regulated
apoptosis (34). Interestingly, our data suggests that the relevant “activator” protein can vary
quite significantly in neoplastic cells. While an “activator” is always necessary for cell
death, the cellular environment or driving oncogene can dramatically shift the precise BH3-
only family member that is most relevant for therapy-induced apoptosis. This context-
dependent relevance of apoptotic regulators may underlie the significant challenge in
eradicating disseminated malignancies and highlights the need to understand the relationship
between intrinsic and paracrine signals and Bcl-2 family regulation.
An unexpected finding from this work is that while Caspase 8 and Bid are expressed at
similar levels in diverse tumor-bearing locations in vivo, they are specifically required for
drug efficacy in the thymus. Examined in isolation, this result would suggest that the thymus
is a pro-death microenvironment. However, previous studies in thymectomized mice have
shown that the thymus can exert a net protective effect on tumor cells following doxorubicin
treatment (9). This cytoprotective effect is mediated in a paracrine fashion by thymic
endothelial cells that secrete multiple pro-survival cytokines in response to DNA damage.
Cytokine induction subsequently upregulates BCL-xL and promotes the survival of target
tumor cells. Thus, the unique role of death receptor activity in this context may function to
counterbalance unchecked survival signaling following cellular stress in the thymic
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microenvironment. Notably, however, the precise mechanism of death receptor engagement
in this context remains to be determined. Addition of recombinant death receptor ligands,
such as FASL, TNF, and TRAIL in vitro fails to induce lymphoma cell death. Consequently,
the engagement of death receptor signaling, like survival signaling, may require a more
complex concerted action of secreted factors and cell-cell or cell-stromal interactions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Examining the role of the entire Bcl-2 family in therapeutic response
(A) A schematic depicting the difference between single and pool-based evaluation of
shRNA composition. (B) A diagram illustrating the Luminex-based shRNA PCR strategy.
PCR primers were designed from constant regions flanking all hairpins. After PCR
amplification, a biotinylated primer is used to measure hairpin abundance, and the unique
fluorescence of the luminex bead distinguishes hairpin identity. (C) A comparison of the
bead-based quantification of hairpin representation following doxorubicin treatment with
single cell flow cytometry measurements (18). (Left) Bead-based measurements are plotted
against each corresponding single hairpin measurements. (Right) Heat maps comparing
shRNA enrichment and depletion using bead-based and flow cytometry approaches. (D) A
heat map comparing the impact of depleting each Bcl-2 family hairpin on the response to
doxorubicin treatment in Eμ-MYC p19Arf−/− lymphomas and p185 BCR-Abl+ p19Arf−/− B-
ALLs. The asterisk demarcates the differential impact of suppressing the BH3-only protein
Bim on doxorubicin sensitivity in these two cell types. (E) p185 BCR-Abl+ p19Arf−/− cells
were treated for 12 hrs at an LD90 of the indicated compounds and analyzed for Bim levels
by western blot.
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Figure 2. An in vivo shRNA screen for modulators of doxorubicin response
(A) A diagram depicting the in vivo screening strategy. Pooled shRNAs targeting Bcl-2
family members were retrovirally transduced into Eμ-MYC p19Arf−/− lymphomas. shRNA
composition was measured either following the presentation of palpable tumor burden or
following tumor relapse after treatment with 8mg/kg doxorubicin. (B) A comparison of the
coefficient of variation (CV) for hairpins targeting the Bcl-2 family in cell culture versus in
vivo screens using a Luminex measurement methodology. (C) An analysis of the distribution
of shRNA CV values for a large in vitro versus in vivo screening data set generated by high-
throughput sequencing. The vertical line represents the CV threshold used to filter in vivo
data. The arrows denote averages for validated hairpins relative to all hairpins (D) Bcl-2
family “hits” following filtering for CV and enrichment criteria and separated by anatomical
niche. The asterisk denotes a Bcl-w shRNA that scored as enriched in the thymus, but was
excluded due to the lack of Bcl-w expression in this context.
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Figure 3. Bid potentiates doxorubicin efficacy in the thymus
(A) A graph depicting an in vivo GFP competition assay in lymphoma cells partially
transduced with shBid-1. Mice were injected with partially transduced lymphoma
populations. At tumor onset all mice were treated with 10mg/kg doxorubicin. 72 hours after
treatment, mice were sacrificed and surviving lymphoma populations were harvested. Fold
change in GFP percentage was assessed 48 hours later (n≥4). (B) H&E stained sections
from mice bearing vector control or shBid thymic lymphomas. Mice were treated with
10mg/kg doxorubicin and sacrificed 48 hours later. Representative fields from treated and
untreated are shown at 25x magnification. Dark patches in treated vector control tumors
indicate sites of normal lymphocyte infiltration.
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Figure 4. Bid status affects therapeutic outcome in vivo, but not in vitro
(A) A Kaplan-Meier curve showing tumor free survival in mice bearing vector or shBid
lymphomas. All mice were treated with a single dose of 10mg/kg doxorubicin (n≥10).
(Inset) A western blot showing Bid protein levels in the presence of Bid shRNAs. (B) A
dose response curve showing the relative viability of lymphoma cells treated with
doxorubicin in vitro for 48 hours. Lymphoma cells were transduced with either a vector
control or an shRNA targeting Bid.
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Figure 5. The extrinsic death pathway mediates doxorubicin response in the thymusx
(A) A Kaplan-Meier curve showing tumor free survival of mice bearing vector, shBid or
shCaspase 8 expressing lymphomas. All mice were treated with a single dose of 10mg/kg
doxorubicin (n≥10). (B) A Kaplan-Meier curve showing the tumor free survival of
thymectomized mice transplanted with pure populations of lymphoma cells transduced with
shBid or a vector control. All mice were treated with a single dose of 10mg/kg doxorubicin
(n=6 for both cohorts).
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